7. Arrhythmia Therapy Update

Acebutolol Therapy for Ventricular Arrhythmia

The safety and efficacy of acebutolol in suppressing ventricular ectopy was evaluated in 60 males (average age 59 years) using 24-hour Holter recordings and a double-blind, randomized, crossover protocol. Acebutolol, 200 mg and 400 mg thrice daily, was compared with placebo. Only patients who had a mean of at least 30 ventricular premature complexes (VPCs) per hour on three 24-hour control Holt...

Protective Role of Nitric Oxide Against Cardiac Arrhythmia An Update

Nitric oxide (NO), a ubiquitous cell signalling molecule, plays an important role in the regulation of cardiovascular function. NO is produced by all cell types in the heart and is widely implicated in vasodilation, inflammation, ischemic preconditioning and cell death. Mounting evidence now suggests that NO also provides protection against cardiac arrhythmia. Pharmacological studies using NO p...

A genetic framework for improving arrhythmia therapy.

Abnormalities in heart rhythm continue to cause high rates of illness and death. Better treatment could be provided by solving two main challenges: the early identification of patients who are at risk, and the characterization of molecular pathways that culminate in arrhythmias. By analysing mechanisms that increase susceptibility to arrhythmia in individuals with genetic syndromes, it might be...

Use of Bemer Therapy with Cardiac Arrhythmia

Special consideration should be given to atrial flutters and atrial fibrillation, when there is a sudden onset of rapid contractions of the atrial muscles. Atrial flutter occurs mostly in people with organic heart disease and is coupled with a frequency of 250-350 heartbeats per minute. The more frequently occurring atrial fibrillation is characterized by random fibrillations of the atrium with...

Update in Surfactant Therapy